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THE IMPACT OF SUBTHERAPEUTIC INITIAL DOSING ON ADHERENCE
TO ANTI-DEPRESSANTS IN THE TREATMENT OF DEPRESSION AND/OR
ANXIETY
Able S1, Bledsoe S1, Gelwicks SC2, Watson PR1
1Eli Lilly and Company, Indianapolis, IN, USA, 2Lilly USA, LLC, Indianapolis, IN, USA
OBJECTIVES: Physician decisions regarding initial anti-depressant dosing levels may
impact treatment outcomes. This study examined initial dosing levels and their associa-
tions with adherence among currently available selective serotonin and serotonin-
norepinephrine reuptake inhibitors (SSRIs and SNRIs). METHODS: A total of 
115,284 patients initiating treatment on an SSRI or SNRI during 2005 were selected
for analysis from a large managed-care claims database. Patients were assigned to a
drug cohort on the basis of their most recent prescription for one of the studied medi-
cations. The study included only patients with one or more ICD-9 coded diagnoses
for depression or anxiety within / 3 months of initiation of treatment with their
index drug, an initial 30 days supply of the index medication, and continuous eligibil-
ity of at least 6 months prior and 12 months following treatment initiation. Subthera-
peutic dosing levels of each studied medication were determined on the basis of label 
information. Outcome measures included early discontinuation (no second prescrip-
tion following initiation) and days on therapy with the index medication. All reported
differences were signiﬁ cant at the 0.01 level. RESULTS: A total of 13.6% of all study
patients initiated antidepressant treatment at a subtherapeutic dose. The share of 
patients initiating treatment at subtherapeutic levels varied substantially across medi-
cations: paroxetine, most frequently (30.1%) and escitalopram, least frequently
(2.7%). Across all studied medications, subtherapeutic initial dosing was associated 
with higher levels of early discontinuation (29.9%) and fewer average days on therapy 
(164.1) than initial dosing at therapeutic doses or higher (24.3% and 176.8 days,
respectively). These associations were directionally consistent across all studied medi-
cations. CONCLUSIONS: Initial dosing of antidepressants at subtherapeutic levels 
was associated with more frequent early discontinuation and fewer average days on 
treatment. Prescribers should be cognizant of the potential impact of initial dosing 
decisions on subsequent adherence to therapy.
PMH82
PATTERNS OF AUGMENTATION OF EXTENDED-RELEASE STIMULANTS
FOR ADHD WITH IMMEDIATE-RELEASE STIMULANTS IN ADULTS
Xiao X1, Damaraju C2, Durkin M2
1XYX Consulting Service Inc, Paoli, PA, USA, 2Ortho-McNeil Janssen Scientiﬁ c Affairs, LLC, 
Titusville, NJ, USA
OBJECTIVES: To examine patterns of augmentation of extended-release (ER) stimu-
lant regimens with immediate-release (IR) stimulants in an adult population, identify 
the factors associated with these patterns, and quantify those factors’ effects on likeli-
hood of augmentation. METHODS: Patients 18 years of age or older with prescription
claims for at least a 90-day supply from June 2005 to May 2006 for 1 of the following 
ER stimulants indicated for attention-deﬁ cit/hyperactivity disorder (ADHD)—ER dex-
methylphenidate (DEX-XR), ER mixed amphetamine salts (MAS-XR), or osmotic-
release oral system methylphenidate (OROS MPH)—and no ADHD medication use 
in the prior 180 days were selected from a large managed care database. Descriptive
statistics were reported for age, gender, health plan type, region, physician specialty, 
dose level, selected comorbidities, and stimulant cost by augmentation status and by 
ER stimulant. Chi-square tests were performed to assess differences in categorical
variables, and Student t tests were used to detect differences for mean age. A logistic
regression model for predicting positive augmentation status was formulated using
backward stepwise regression to evaluate the inclusion of potential explanatory vari-
ables. RESULTS: Of the 3234 adult patients eligible, 13.8% had IR augmentation 
with a mean incremental IR drug cost of $15.91 per month. Signiﬁ cant covariates for
the logistic model were health plan type (P  0.0022), bipolar disorder diagnosis (P 
0.0269), ER product (P  0.0001), and dose level (P  0.0345). Likelihood of aug-
mentation was higher with plan type “Other” i.e., not HMO, PPO, or POS), a diag-
nosis of bipolar disorder, use of DEX-XR or MAS-XR, and dose level of “medium.”
CONCLUSIONS: While this observational study quantiﬁ ed important aspects of the
augmentation of ER stimulants with IR stimulants from a claims data perspective,
more research is needed to identify the reasons for augmentation in adults with ADHD 
(e.g., duration of effect, titration) and to examine patterns of medication taking 
throughout the day.
PMH83
FACTORS THAT INFLUENCE DECISIONS AMONG MBHO NETWORK 
PHYSICIANS TO USE OFFICE-BASED OPIOID TREATMENT OR TO 
INCREASE THE NUMBER OF OPIOID-DEPENDENT PATIENTS THEY 
TREAT: RESULTS FROM THE OBOT ATTITUDE AND INTENTION
PHYSICIAN SURVEY
Ruetsch C, Schoenberger C
Health Analytics, LLC, Columbia, MD, USA
OBJECTIVES: Although more than 9,000 physicians are certiﬁ ed to prescribe
buprenorphine for opioid dependence (OD), many patients are unsuccessful in access-
ing outpatient OD treatment. Efforts to improve access to ofﬁ ce-based opioid treat-
ment (OBOT) have focused primarily on physician reimbursement or education. To
our knowledge, none have directly queried physicians about factors they view as limi-
tations to treating more OBOT patients. The goal of this study was to understand the
reasons why some providers choose to maintain OBOT patient caseloads below capac-
ity. METHODS: In June 2007, a mail-based, 41-item survey to measure physician 
attitudes, beliefs, and experiences in chronic disease, addiction, and OD was sent to 
a national sample of 621 managed behavioral health care network physicians certiﬁ ed 
to prescribe buprenorphine. Respondents rated the degree to which 11 different sce-
narios independently affect their decision to use OBOT or to increase the number of 
OD patients they treat. Results are reported in terms of physician endorsement (i.e. 
the extent to which each of 11 situations inﬂ uences treatment decisions). The primary 
outcomes measure was the number of OD patients that physicians treat with OBOT. 
RESULTS: The response rate was 47.6% (296 physicians). The ﬁ ve most commonly
endorsed barriers were concerns about coordinating logistics like urine tests (51.3%);
attracting opioid-dependent patients to their practice (50.0%); patients selling 
buprenorphine or taking more than prescribed (48.4%); being available 24/7 for
OBOT patients (48.3%); and ability to send challenging patients to appropriate treat-
ment programs (42.9%). CONCLUSIONS: Managed Care Organizations can improve 
access to OBOT by providing network physicians with logistical guidance and ofﬁ ce
management resources, such as lab testing kits, key opinion leadership, and referrals 
to local treatment centers.
PMH84
AN ASSESSMENT OF THE IMPACT OF AN EDUCATIONAL PHARMACY
MANAGEMENT INTERVENTION ON PRESCRIBERS TO MEDICAID
BENEFICIARIES
Esposito D1, Verdier JM2
1Mathematica Policy Research, Inc, Princeton, NJ, USA, 2Mathematica Policy Research, Inc, 
Washington, DC, USA
OBJECTIVES: To examine whether educational mailings to prescribers of psychotro-
pic medications to Medicaid beneﬁ ciaries improve patient quality of care and reduce 
drug costs. METHODS: Prescribing behavior was compared to pre-intervention
behavior and, where available, to the behavior of prescribers who were not sent mail-
ings. Medicaid pharmacy and eligibility data from April 2003 through September 
2007 were used, as well as data on intervention mailings and deviations from clinical 
guidelines (from which the treatment group was identiﬁ ed). Primary outcome measures 
included clinical deviations, psychotropic claims, and psychotropic costs as a percent-
age of total psychotropic claims or costs. Intervention effects were estimated with
generalized linear regression models controlling for prescriber-level ﬁ xed effects
and a time trend, including sensitivity analyses for various prescriber subgroups. In 
Phase I (March 2004 to November 2005) mailings were sent monthly to qualifying 
prescribers (297; 221 comparison) and in Phase II (March 2006 to January 2007) 
mailings were alternated between prescribers to children (89; 82 comparison) and 
prescribers to adults (145; 354 comparison). RESULTS: Impacts were small and
generally not statistically signiﬁ cant. Prescribing behavior in Phase I and for pre-
scribers to adults in Phase II was not different from existing trends (p  0.10 for 
all outcomes). For prescribers to children, intervention period trends were statistically
different from pre-existing ones for all outcomes; however, they were not different 
when compared with comparison group prescribers. For example, targeted claims 
as a percentage of total claims for treatment group prescribers were slightly lower 
than for the comparison group, but the average difference was less than 1 percentage
point (p  0.12). Effects for all outcomes were not signiﬁ cant until 12 months 
into the intervention. CONCLUSIONS: Psychotropic medications are commonly 
prescribed to Medicaid beneﬁ ciaries. An educational intervention consisting of 
only prescriber mailings is likely not sufﬁ cient to improve quality of care or reduce 
drug costs.
PMH85
PATTERNS OF AUGMENTATION OF EXTENDED-RELEASE STIMULANTS
FOR ADHD WITH IMMEDIATE-RELEASE STIMULANTS IN CHILDREN
AND ADOLESCENTS
Xiao X1, Damaraju C2, Durkin M2
1XYX Consulting Service Inc, Paoli, PA, USA, 2Ortho-McNeil Janssen Scientiﬁ c Affairs, LLC, 
Titusville, NJ, USA
OBJECTIVES: To examine patterns of augmentation of extended-release (ER) stimu-
lant regimens with immediate-release (IR) stimulants in a child and adolescent popula-
tion, identify the factors associated with these patterns, and quantify those factors’
effects on likelihood of augmentation. METHODS: Patients with ADHD 6 to 17 years 
of age with prescription claims for at least a 90-day supply from June 2005 to May
2006 for 1 of the following ER stimulants indicated for attention-deﬁ cit/hyperactivity 
disorder (ADHD)—ER dexmethylphenidate (DEX-XR), ER mixed amphetamine salts 
(MAS-XR), or osmotic-release oral system methylphenidate (OROSMPH)—and no 
ADHD medication use in the prior 180 days were selected from a large managed care
database. Descriptive statistics were reported for age, gender, health plan type, region, 
physician specialty, dose level, selected comorbidities, and stimulant cost by augmenta-
tion status and by ER stimulant. Chi-square tests were performed to assess differences 
in categorical variables and Student t tests were used to detect differences for mean 
age. A logistic regression model for predicting positive augmentation status was for-
mulated using backward stepwise regression to evaluate the inclusion of potential
explanatory variables. RESULTS: Of the 5764 eligible patients, 9.5% had IR augmen-
tation with a mean incremental IR drug cost of $22.88 per month. Signiﬁ cant covari-
ates for the logistic model were age (P  0.0171), physician specialty (P  0.0065), 
anxiety diagnosis (P  0.0001), bipolar disorder diagnosis (P  0.0022), and ER 
product (P  0.0001). Likelihood of augmentation was higher with increased age, 
psychiatrist specialty, the presence of diagnoses of anxiety or bipolar disorder, and use 
of DEX-XR. CONCLUSIONS: While this observational study quantiﬁ ed important 
aspects of the augmentation of ER stimulants with IR stimulants from a claims data 
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perspective, more research is needed to identify the reasons for augmentation in chil-
dren and adolescents with ADHD (e.g., duration of effect, titration) and to examine 
patterns of medication taking throughout the day.
PMH86
CONTINUITY OF CARE FOLLOWING HOSPITALIZATION FOR
BIPOLAR DISORDER IN PRIVATE PAYER CLAIMS
Stensland MD1, Peng X2
1Eli Lilly and Company, Indianapolis, IN, USA, 2Lilly USA, LLC, Indianapolis, IN, USA
OBJECTIVES: Poor continuity of care occurs when patients do not follow-up after 
being discharged from the hospital. In bipolar disorder problems with continuity of 
care and medication adherence may lead to expensive relapses. The objectives of this
research were threefold: 1) examine the frequency of poor continuity of care for indi-
viduals with bipolar disorder; 2) identify the predictors of poor continuity of care; 
and 3) evaluate the potential increased psychiatric hospitalization costs. METHODS:
Premier linked their PerspectiveTM Comparative Database (PCD), the largest, most
detailed, U.S. hospital database, with the administrative claims from a large managed 
care organization. We identiﬁ ed 319 individuals who had a primary discharge diag-
nosis of bipolar disorder in the PCD and who maintained continuous eligibility for
the 60 days prior and the 180 days following the hospitalization. Good continuity of 
care was operationally deﬁ ned as the presence of a psychiatric visit in the 60 days 
following discharge. Propensity scores were used to correct for background differences
between patients with good continuity of care and patients with poor continuity of 
care. RESULTS: A total of 34.5% of individuals had poor continuity of care. Prior to
discharge, individuals who would later have poor continuity of care could be identi-
ﬁ ed. Some variables that independently predicted later poor continuity of care included
no psychotherapy visits, no psychiatric visits, substance use diagnoses, and psychiatric
hospitalizations. After correcting for background differences, patients with poor con-
tinuity of care had reduced mood stabilizer use (94 vs. 116 days, p  0.008) and twice 
the psychiatric hospitalization charges ($10,027 vs. $4,892, p  0.03). CONCLU-
SIONS: One in three individuals with bipolar disorder did not have a psychiatric 
follow-up visit after discharge from the hospital. This poor continuity of care appears
to lead to decreased medication adherence and increased psychiatric hospitalizations.
An effective, targeted intervention could potentially prevent relapses and reduce health 
care costs.
PMH87
TREATMENT PATTERNS BY RACE/ETHNICITY AND INCOME LEVELS
AMONG ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) 
SUBJECTS TREATED WITH SHORT-, INTERMEDIATE-AND LONG-ACTING
STIMULANTS
Christensen L1, Sasane R2, Hodgkins P2, Harley C3
1i3 Innovus, Ann Arbor, MI, USA, 2Shire Pharmaceuticals, Wayne, PA, USA, 3i3 Innovus, Eden
Prairie, MN, USA
OBJECTIVES: This research examines the relationship of ethnicity and income with 
attention-deﬁ cit hyperactivity disorder (ADHD) treatment patterns among subjects on 
medications of different durations. METHODS: Claims of newly treated ADHD sub-
jects, aged q6 years, initially treated with stimulants, and continuously enrolled in a
US commercial health plan 6 months prior and 12 months after their ﬁ rst prescription 
(January 1, 2004 “C September 30, 2006) were studied. Subjects took short- (SAS)
intermediate- (IAS) or long-acting (LAS) stimulant medication for ADHD. Persistence 
was deﬁ ned as the number of days on initial therapy. Adherence was deﬁ ned as the 
number of days of initial therapy divided by persistent days. Differences in mean per-
sistence and adherence, dosing, switching and augmentation among ethnicities (non-
Hispanic Caucasians [NHC], Hispanics [H] and African Americans [AA]) and among 
income levels were assessed. RESULTS: Among children on LAS (n  12,796), NHC 
had the highest mean adherence (0.56) and the longest mean persistence (251 days) 
(p  0.0001 among groups), while AA had the shortest persistence (222 days) and the
lowest adherence (0.46) (p  0.0001 among groups). Similarly, among adults receiving 
LAS (n  8422), NHC had the highest adherence (0.58) and the longest persistence 
(225 days). Persistence was again shortest among AA (194 days; p  0.037 among 
groups), while adherence was equally low for AA and H (0.52; p  0.002 among 
groups). Within treatment groups of different durations, the propensity of subjects to 
change dose, switch or augment their medication varied according to ethnicity. While 
no signiﬁ cant relationship between race/ethnicity and either adherence or persistence 
was found among children or adults receiving SAS or IAS, the IAS and LAS groups 
showed greater persistence and adherence with increased income levels in some sub-
jects. CONCLUSIONS: Persistence and adherence to stimulant medications differed 
by race/ethnicity and income. This may have implications for the optimal management
of ADHD.
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A SYSTEMATIC EVALUATION OF PUBLISHED LITERATURE TO ASSESS 
BURDEN OF TREATMENT-RESISTANT DEPRESSION
Cyr P1, Bockstedt L2, Olchanski N1, Halseth M2, Partlow K3, Lindeke C2, Handke B2, 
Goss T3
1Boston Healthcare Associates, Inc, Boston, MA, USA, 2Medtronic Neuromodulation, Fridley, 
MN, USA, 3Boston Healthcare Associates, Inc, Washington, DC, USA
BACKGROUND: Treatment-resistant depression (TRD) is severely disabling with no
treatments proven to provide sustainable beneﬁ t when multiple medications, psycho-
therapy, and electroconvulsive therapy fail. (Malone, 2008). OBJECTIVES: The 
perform a systematic review of published literature to evaluate recent health economics
and outcomes research related to TRD to inform future research initiatives. 
METHODS: English language citations in PubMed and Cochrane Library from 
January 1, 2000–October 1, 2008 were systematically reviewed. Standard search terms
deﬁ ned disease states (including TRD, severe depression (SD), chronic depression
(CD), major depressive disorders (MDD), and suicidality); interventions (deep brain
stimulation, electroconvulsive therapy, transcranial magnetic stimulation and vagus
nerve stimulation); and outcomes (treatment outcomes, presenteeism, symptom
burden, resource utilization, productivity, cost, economics, and quality of life(QOL)). 
RESULTS: Initial searches yielded 8811 citations, narrowed to 5626 using date and 
language criteria. Title review further narrowed literature (reasons: not related to 
depression ^70%, clinical trials of antidepressant medications ^20%, and review/case 
studies ^10%), resulting in 411 unique abstracts for review and forty publications for 
abstraction. Clinical studies were most frequent (n  16) and economic models least 
frequent (n  3); a majority (n  22) reported a U.S. patient population. Thirteen 
publications reported on TRD, thirteen on MDD, and six reported on a “general 
depression” population. Reported deﬁ nitions of TRD varied greatly (one medication
failure (n  2), two medication failures (n  6), HAM-D score (n  3), diagnosis/treat-
ment algorithm (n  1), not deﬁ ned (n  1)). HAM-D (n  12) and MADRS (n  9) 
were the most frequently reported clinical outcomes measures. Cost outcomes were 
discussed in thirteen reports (direct costs (n  11), indirect costs (n  2)). CONCLU-
SIONS: Deﬁ nitions of TRD or CD reported in the literature vary substantially, and 
studies examining productivity of patients were conﬁ ned to generic depression or
MDD populations and would not be directly comparable to a CD or TRD population. 
Additional research is necessary to better deﬁ ne the cost and patient burden of 
TRD.
NEUROLOGICAL DISORDERS – Clinical Outcomes Studies
PND1
PREVALENCE OF INSOMNIA IN EUROPE: A COMPARISON OF FIVE
COUNTRIES
Narayanan S1, Potthoff P2, Guether B2
1TNS Healthcare, New York, NY, USA, 2TNS Healthcare, Munich, Bavaria, Germany
OBJECTIVES: To assess the prevalence of insomnia among ﬁ ve large European 
nations. METHODS: TNS Healthcare’s European Healthcare Panel of individuals in
France, Germany, Italy, UK and the Netherlands were surveyed in 2007 to assess 
disease burden at national level. The self-reported epidemiological data is representa-
tive of population gender and age (18–24,25–34,35–44,45–54,55–64,65–69yrs) strata 
in respective countries, ensured by sampling and intensive panel management. The
survey collected information on select health conditions (incl. insomnia/sleeping-
problems; in the past 12-months), quality of life and health care-utilization. RESULTS:
Total of over 160,000 adult individuals in the European Healthcare Panel com-
pleted survey in the ﬁ ve European nations. Prevalence of Insomnia varied widely
between these 5 nations, as follows (All, Male, Female, % individuals): Netherlands:
13.5%,9.2%,18.0%; Italy: 18.5%,13.3%,23.6%; U.K: 19.3%,14.7%,24.0%;
Germany: 21.6%,16.2%,27.0%; France: 27.6%,19.9%,35.0%. Within each country, 
burden of Insomnia varied by age and gender; distribution among male (18–24,
25–34,35–44,45–54,55–64,65 yrs: % pts) was: the Netherlands: 6.4%,8.5%,8.1%,
10.9%,11.0%,8.9%; Italy: 11.1%,8.9%,12.6%,15.7%,16.1%,18.9%; U.K: 9.8%,
10.8%,16.6%,18.1%,17.0%,12.9%; Germany: 12.8%,14.1%,17.1%,19.6%,18.0%,
11.6%; France: 15.9%,17.8%,21.2%,24.0%,19.5%,18.9%; distribution among 
female (18–24,25–34,35–44,45–54,55–64,65 yrs: % pts) was: the Netherlands:
8.5%,12.5%,15.5%,23.7%,23.4%,25.6%; Italy: 16.9%,19.1%,22.4%,28.0%,
27.2%,27.2%; U.K: 17.1%,18.2%,23.0%,30.1%,30.0%,24.8%; Germany: 23.3%,
23.5%,26.5%,32.0%,27.6%,26.2%; France: 28.5%,29.6%,34.2%,39.9%,40.3%,
37.2%. General Practitioners were the primary point of diagnosis and source of treat-
ment, even though this statistic varied between the countries. CONCLUSIONS: Preva-
lence of insomnia appears to be substantial in the studied European nations, with 
France bearing the most burden (one-in-ﬁ ve and one-in-three males and females
respectively in France suffered from this condition). Prevalence peaked among the 
45–64 age-group across the countries. Females had substantially higher disease burden
across the countries, amounting to as much as 1.5 to 2 times more than their male
counterparts in certain age groups.
PND2
CHRONIC MIGRAINE CRITERIA AND THEIR EFFECTS ON GLOBAL
PREVALENCE ESTIMATES: A SYSTEMATIC REVIEW
Natoli JL1, Manack A2, Dean BB1
1Cerner LifeSciences, Beverly Hills, CA, USA, 2Allergan, Inc., Irvine, CA, USA
OBJECTIVES: The deﬁ nition of chronic migraine (CM), as opposed to episodic 
migraine, has evolved over 20 years of clinical study. This systematic review summa-
rized population-based studies reporting CM prevalence and examined how variations 
in deﬁ nitions affected estimates. METHODS: We conducted a systematic search 
of PubMed, Cochrane, and EMBASE. Search terms included chronic migraine, 
transformed migraine, chronic headache, and prevalence. We included population-
based studies in adults and mixed adults/adolescents that estimated CM prevalence
(or provided information to calculate estimates). We deﬁ ned chronicity as a minimum
headache frequency of 10 per month or reported “daily” headache. Where equivalent, 
we combined diagnostic criteria and deﬁ nitions. Findings were qualitatively summa-
rized. RESULTS: Sixteen publications representing 12 unique studies were identiﬁ ed.
